The academy will consist of three modules which will be launched in 2021. Those who complete all three modules will receive certification from Bimeda, and some exclusive branded goodies.
The first module is titled Bimeda Trace Elements in Dairy Cow Fertility & Pregnancy and is available now on Bimeda’s e-learning portal: https://bimeda-learning.co.uk. This module also accounts for 1 hour 15 minutes of CPD and vets can download a certificate when they complete the module. The module has also been accredited with 9 AMTRA points.
In the coming months Bimeda says it'll add a second module focused on the role of trace element nutrition in lamb and calf growth, and a final module focused on the role of trace elements in sheep fertility and pregnancy.
Bimeda UK General Manager Mark Cokayne said: "Trace elements play a critical role in the health and fertility of ruminants, yet historically this area has been somewhat overlooked in formal animal health education.
"Our customers tell us that they would like a deeper understanding of areas such as trace element deficiencies, toxicities and interactions, and the impact of these on ruminant health and fertility. We are pleased to respond to this market demand with our new academy, which will provide veterinarians and SQPs with additional knowledge to help inform their conversations with farmers."
To sign up to either Bimeda’s online Nutrition Academy or the Sheep Scab Academy, visit https://bimeda-learning.co.uk
For more information, speak to your Bimeda territory manager or call Bimeda on 01248 725 400.
James Hutchings, Head of Sales for Bimeda UK, said: "The launch of Tetroxy Vet highlights our ongoing commitment to providing UK veterinarians with a choice of high quality veterinary pharmaceuticals at a fair price."
Bimeda says the benefits of Tetroxy Vet include:
Tetroxy Vet is available in a 100ml pack size.
Bimeda has announced the launch of Bilovet, a new tylosin-based antibiotic for cattle and pigs.Padraig Hyland, Head of Technical Veterinary Services at Bimeda said: ''It is with great pleasure that I announce the launch of our much anticipated Bilovet 200 mg/ml solution for injection for cattle and pigs as the latest addition to Bimeda's range of essential antibiotics.
Bilovet contains Tylosin 200 mg/ml and is the second Tylosin-based injectable antibiotic to be licensed for cattle - including dairy cattle - in the UK. Bilovet is licensed in cattle for the treatment of respiratory infections, metritis, mastitis, interdigital necrobacillosis and calf diphtheria as well as a range of pig infections, including enzootic pneumonia, haemorrhagic enteritis, erysipelas, arthritis and metritis".
Bimeda's Head of Bimeda R+D, Xavier Molins said: "Bilovet is a completely new development for a product that includes a new species (cattle). Bimeda have made a significant investment in bringing Bilovet to market, including conducting new Environmental Risk Assessment studies according to current guidelines and regulations.''
For more information, ring 01248 725 400 or email: uksales@bimeda.com
Bimeda UK has announced that Endofluke 100mg Oral Suspension has been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml) kills all three stages of liver fluke.
Bimeda UK Sales Manager, Andrew Lane said: "This is great news for the UK's dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK's dairy farmers."
Endofluke is a POM-VPS product.
For more information, visit www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on alane@bimeda.com or on 07917 208524.
Bimeda has launched Recocam, a 20mg/ml meloxicam preparation licensed for use as a single injection course in cattle, horses and pigs.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "Meloxicam's anti-inflammatory credentials and safety profile is well proven and it remains rightly popular with large animal vets. With our manufacturing expertise it makes sense to add this widely used product to our portfolio. Our aim is to provide a comprehensive range of both established standards and new innovative products for cattle and equine vets, and this is just another step in that process."
Bimeda says Recocam has a broad range of indications including acute respiratory infections, in combination with oral re-hydration in diarrhoea therapy and acute mastitis, for non-infectious locomotor disorders and lameness in pigs and alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and pain relief associated with equine colic. In cattle Recocam can be given by single subcutaneous or intravenous injection.
Bimeda has announced the launch of Butagran Equi (phenylbutazone), to join its range of analgesics and anti-inflammatories.
Bimeda says that Butagran Equi provides rapid onset of activity with the added convenience for horse owners or professionals of being presented as an easy-to-administer sweetened powder.
Indications include musculo-skeletal conditions that require relief from pain and a reduction in the associated inflammation, including lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Head of Bimeda technical services Padraig Hyland MVB said: "Butagran Equi is particularly suited where continued mobility is considered desirable. It is also of value in limiting post-surgical inflammation, myositis and other soft tissue inflammation and can be used as an anti-pyretic where this is considered advisable, such as in viral respiratory infections. And being a sweetened powder it's quite straightforward for horse owners to administer and dose as prescribed."
He added: "Butagran Equi follows the launch of a number of new products and is proof our desire to provide a comprehensive and relevant equine portfolio backed up with first class technical support."
Bimeda has announced the launch of a new teat seal which the company claims offers a significant return on investment and an opportunity for veterinary surgeons to prompt farmers to re-evaluate their dry cow therapy and mastitis control.
Bimeda's vet and head of technical services, Padraig Hyland MVB said: "Boviseal is proven to dramatically reduce mastitis in the 100 days post calving¹. Adding competition to the market will encourage farmers to re-assess their dry cow and mastitis strategies.
"The UK launch of Boviseal is a great opportunity for vets to raise the issue of the damage and cost of mastitis, and the potential savings by the correct use of a seal. Boviseal is the number one selling teat seal in the Republic of Ireland, with 2/3 of the Irish dairy cows sealed annually²."
Padraig says the evidence of the value from combined sealing and antibiotic therapy is all too clear when it comes to dry cow therapy. He cites a case study at Waterwheel Farm in Donegal, Ireland which delivered a 300% return on investment: "Combined therapy might sound costly but this two year study saw annual mastitis cases fall dramatically, from 26 per 100 cows to 9 per 100³.
"Defra figures indicate that mastitis is the most costly disease problem that UK dairy farmers face, with a typical case costing £175.00 4. When you compare that against the cost of treatment for the herd, there's no real counter argument in my opinion."
Boviseal contains 65% Bismuth Subnitrate. Padraig says the effectiveness of teat sealing is proven but correct administration is key: "It is important to note that the conventional practice of massaging into the udder after infusion is not employed - the teat seal must stay in the teat canal."
For details on best application practices, the company has developed a website, www.boviseal.co.uk with a video demonstration for correct infusion.
For further information, visit the website or contact Bimeda on 01248 725400.
References
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
1. 1987 (Taranaki, North Island)